



ViroGates announces CE-IVD approval and launch of suPARnostic® TurbiLatex on the Abbott Labs Architect Clinical Chemistry Platform

12.6.2020 12:34:38 CEST | ViroGates | Company Announcement

Company Announcement No. 14-2020 -12 June 2020

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces that it has completed the development and regulatory approval (CE-IVD) of its suPARnostic® TurbiLatex product for the Abbott Architect 4000, 8000 and 16000 platform, which allows for clinical use of suPARnostic® TurbiLatex on the Abbott Architect instruments. This is ViroGates' first validation of the suPARnostic® TurbiLatex product on an Abbott instrument line. Abbott Laboratories is a global medical technology company with a diagnostics division, that has a turnover of 7.7 billion USD.

The Abbott system can run up to 1,800 blood samples per hour and work as a fully automated system requiring no manual handling from the blood sampling until results are processed. The approval of suPARnostic® TurbiLatex for the Architect platform complements the previous approvals for the Roche Diagnostics cobas systems and the Siemens ADVIA XPT system. The validation was done in collaboration with the French hospital, Hospices Civils de Lyon.

The suPARnostic® TurbiLatex product is a pivotal element in ViroGates' European expansion strategy with a special focus on the acute care market, valued at approximately 1 billion EUR annually for the suPARnostic® analysis.

CEO Jakob Knudsen, says in a comment: *"We are excited to offer suPARnostic® TurbiLatex for the Abbott Architect platform that serves many hospitals in Europe. Several hospitals have already enquired about this validation for clinical use in markets such as France, Spain and Italy. We look forward to implement suPARnostic® TurbiLatex at these hospitals to support faster and better patient triage decisions to the benefit of patients, hospitals, and payers. From a development point of view it is also very encouraging to come to this point where suPARnostic® TurbiLatex can be used at the top three biochemical instrument providers' platforms"*

About the turbidimetric measurement principle: The suPARnostic® TurbiLatex product is based on a technology called turbidimetry that measures the loss of intensity of transmitted light in the blood sample being analysed. The principle of measuring blood samples by using turbidimetry is the basis of almost all central laboratory clinical chemistry platforms in hospitals.

The announcement can be found at <https://www.virogates.com/investor/announcements>

For further information please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is the biomarker detected by ViroGates' suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is a general risk status biomarker indicating disease presence, disease severity and risk of progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics' cobas, instruments, Siemens ADVIA XPT instruments and the Abbott Labs Architect instruments. ViroGates works with partners to develop solutions for other platforms.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

- Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com

Attachments

- [20200612-ViroGates Company announcement 14.pdf](#)